Novel uses of alanyl-glutamine and ophthalmic compositions containing alanyl-glutamine
Alanyl-glutamine compositions address the ineffectiveness of current treatments for ocular surface diseases by promoting epithelial healing and reducing inflammation, providing a safe and effective solution for conditions like corneal epithelial injury and conjunctivitis.
Patent Information
- Application Number
- JP2024532667
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-01
- Filing Date
- 2022-11-23
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for ocular surface diseases and conditions such as corneal epithelial injury, diabetic keratopathy, recurrent corneal erosions, conjunctivitis, ocular congestion, and meibomian gland dysfunction are ineffective, have systemic side effects, and do not address the root cause, leading to prolonged treatment periods and potential eye damage.
The use of alanyl-glutamine in ophthalmic compositions, including eye drops, creams, gels, and patches, to treat and alleviate these conditions by promoting epithelial healing and reducing inflammation.
Alanyl-glutamine compositions effectively treat and alleviate ocular surface diseases and conditions without systemic toxicity, promoting epithelial healing, reducing inflammation, and preventing complications like scarring and vision loss.
Smart Images

Figure 2024542280000001 
Figure 2024542280000002 
Figure 2024542280000003
Abstract
Description
[Technical field]
[0001] The present disclosure relates to the fields of biotechnology and pharmacology, and in particular to novel uses of alanyl-glutamine, and more particularly to the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating non-dry eye ocular surface diseases and / or conditions; the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with corneal epithelial injury; the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with diabetes induced keratopathy; the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with surgery-related recurrent corneal epithelial erosion. The present disclosure further relates to an ophthalmic composition comprising alanyl-glutamine and an ophthalmic solution, the use of alanyl-glutamine in the manufacture of a medicament for treating, reducing or alleviating conjunctival congestion and / or other conditions associated with conjunctivitis (eye redness); the use of alanyl-glutamine in the manufacture of a medicament for treating, reducing or alleviating ocular surface diseases and / or conditions associated with meibomian gland dysfunction; the use of alanyl-glutamine in the manufacture of a medicament for treating, reducing or alleviating ocular surface diseases and / or conditions associated with eye strain; the use of alanyl-glutamine in the manufacture of a beauty and health care product for reducing or alleviating eye strain; and the use of alanyl-glutamine in the manufacture of a beauty and health care product for the eye. The present disclosure further relates to an ophthalmic composition comprising alanyl-glutamine and an ophthalmologically acceptable excipient, the ophthalmic composition being in the form of an eye drop, a suspension, an eye ointment, an emulsion, an eye pad, an eye patch, an eye mask, an eye cream, a spray, a gel, an injection or a leave-in. [Background technology]
[0002] As early as 1984, Nelson proposed the concept of ocular surface disease. Anatomically, the ocular surface includes the entire mucosal epithelial layer between the upper and lower eyelid margins. Histologically, this epithelial layer covers two main areas, namely the cornea and the conjunctiva. The primary function of the ocular surface is to ensure clear vision when the eye is open. The ocular surface includes the corneal epithelium, the conjunctival epithelium, and the tear film. These three are closely related and affect each other. Changes in any of the three result in instability of the ocular surface. Thus, from a narrow perspective, ocular surface disease refers only to diseases of the corneal and conjunctival epithelium. From a relatively broader perspective, ocular surface disease should include superficial corneal and conjunctival diseases as well as diseases that can result in dysfunction of the tear film, i.e., "ocular surface diseases."
[0003] The transparency and functional integrity of the cornea depend on the normal structure and metabolism of the layers of corneal tissue, and the corneal epithelium, located in the outermost layer, undoubtedly plays a very important role in this regard. Various physical, chemical, mechanical injuries, pathogenic microorganisms, endocrine and immune factors can cause corneal epithelial injury. The corneal epithelium is a physical barrier against invasion by external pathogenic agents. The maintenance of its integrity depends on the tight and anchoring junctions between epithelial cells and between cells and the basement membrane, as well as the continuous self-renewal of epithelial cells. Injuries to the corneal epithelial layer can affect its barrier function by affecting the junctions between cells and causing changes in the permeability and selectivity of the cell membrane. This makes the cornea vulnerable to external pathogenic agents, which can lead to inflammation, corneal opacity and even blindness. Due to the destruction of the normal and intact epithelial barrier, persistent corneal epithelial damage may allow pathogenic microorganisms to easily penetrate Bowman's membrane and invade the corneal stroma, causing corneal inflammation, corneal stromal opacification, collagen melting forming corneal ulcers, corneal perforation, and even ocular defects, which may lead to severe consequences. Currently, traditional treatments for persistent corneal epithelial damage include: tear substitutes, corneal contact lenses, tarsorrhaphy, growth factors, autologous serum, etc., which are ineffective.
[0004] Corneal ulcers are open wounds that develop on the superficial cornea as a result of bacterial, viral, or fungal infection, mechanical injury, or severe allergic disease. Corneal ulcers are serious conditions that must be treated quickly to avoid problems with vision loss. Inflammation of the cornea can result in severe vision loss or even blindness due to inflammation or injury. The deeper the corneal ulcer, the more severe the condition, and very deep ulcers can lead to scarring of the cornea, which subsequently blocks light from entering the eye. Treatments usually include antibiotics and antiviral or antifungal drugs. Steroid eye drops may also be given to reduce inflammation. However, no drug enhances wound closure and avoids scarring. In severe cases, if existing treatments have not helped, a corneal transplant may be required to restore vision.
[0005] Diabetic keratopathy (DK) is one of the common complications in diabetic eyes. Its main clinical findings include punctate keratitis, delayed corneal epithelial regeneration, recurrent corneal epithelial erosion, corneal hypoesthesia, and corneal edema. Diabetic keratopathy was first proposed and named by Schultz. It has been reported that 47% to 64% of diabetic patients develop DK. DK is classified into two types: primary DK and secondary DK. Primary DK refers to keratopathy caused by diabetes itself, and secondary DK refers to corneal complications caused by eye surgery in diabetic patients.
[0006] Recurrent corneal erosion occurs when the corneal epithelium is damaged (corneal rupture) and the adhesions between the regenerated epithelium and the basement membrane and Bowman's membrane are not strong enough, causing the incompletely healed corneal injury to rupture again when the eyes are opened after resting with the eyes closed, resulting in recurrence of the symptoms of corneal rupture (including stinging eye, redness, photodysphoria, tearing, inability to open the eye, etc.), while also providing an opportunity for bacteria to cause corneal infection and ulceration.
[0007] The conjunctiva is a transparent membrane covering the inner surface of the eyelids and the surface of the white of the eye at the front of the eye. Most of the conjunctiva is in direct contact with the outside world, so it is easily irritated by infectious agents (such as bacteria, viruses, and chlamydia) and non-infectious agents (such as trauma, chemicals, and physical agents) in the surrounding environment, and the conjunctiva is rich in blood vessels and lymphatic tissue, so it is easily sensitized by the conjunctiva itself and by external antigens. Conjunctivitis is an inflammation or infection that occurs in the conjunctiva. Conjunctivitis is a common disease in ophthalmology and is a general term for inflammatory responses such as edema and redness caused in the conjunctival tissue by external and body's own factors. Conjunctivitis itself does not seriously affect vision, but if the inflammation spreads to the cornea or becomes complicated, it may cause vision damage. Currently, clinical prevention and treatment of conjunctivitis mainly involves external supplementation of artificial tears to reduce the clinical symptoms of conjunctivitis, or topical use of steroid hormones or nonsteroidal anti-inflammatory drugs to reduce inflammation of the ocular surface. Although the above treatments can alleviate some clinical symptoms of conjunctivitis to some extent, they can only treat symptoms, not the underlying cause, and may even cause dependency on external eye drops. In addition, in order to avoid eye infections caused by eye drop application, eye drops often contain preservatives for long-term storage, and long-term use of eye drops containing preservatives is not only unfavorable for treating conjunctivitis, but can also cause dry eyes, pain and itching, thereby worsening the clinical symptoms of dry keratitis / conjunctivitis and causing damage to the corneal epithelium in severe cases. Infectious acute conjunctivitis is a common acute epidemic eye disease caused by bacterial or adenovirus infection. Its main characteristics are obvious conjunctival congestion and purulent or mucopurulent secretions. Bacteria can come into direct contact with the conjunctiva through various media and spread rapidly in collective units such as public places, kindergartens, schools and homes, resulting in epidemics. Typical symptoms of infectious acute conjunctivitis include: 75% of patients have lacrimation, 75% of patients have increased eye discharge, 75% of patients have photophobia, 65% of patients have ocular congestion and redness, and 65% of patients have eye edema.Patients have a stinging sensation in the eyes, heavy eyelids, photophobia and tearing, and if the itching in the eyes is severe, a burning sensation. Temporary blurred vision may be caused by the secretions adhering to the pupillary surface of the cornea, and vision may be restored after drainage. Due to inflammatory stimulation, a large amount of mucopurulent secretions may occur, and patients may wake up with upper and lower eyelids adhered by secretions, and if the lesion infiltrates into the cornea, photophobia, pain, hypopsia and other symptoms will obviously worsen, and a small number of patients may have upper respiratory tract infections or other systemic symptoms at the same time. Currently, the main methods of treating infectious acute conjunctivitis are: washing the conjunctival sac with an appropriate irrigant, such as saline or 2% boric acid in water, and wiping the eyelid margin with a sterile cotton swab; applying eye drops or eye ointments, such as antibiotic eye drops, antiviral eye drops, and hormonal anti-inflammatory drugs, to the affected eye. However, the above-mentioned methods have long treatment periods and serious side effects.
[0008] Ocular congestion refers to the redness of the whites of the eyes when under certain circumstances the blood vessels of the bulbar conjunctiva and scleral tissues become dilated, congested, stop flowing or begin to bleed. Due to the different blood supply sources of the various parts of the eye, the congestion patterns of the eyes are also different and the pathologies reflected are also different. Thus, ocular congestion is a common symptom common to many eye diseases. Ocular congestion is classified into two types: superficial and deep. The superficial is characterized by a light red color and is called "conjunctival congestion"; the deep is characterized by a dark red color and is called "ciliary congestion". The combination of both is called "mixed congestion". Conjunctival congestion represents a primary or secondary disease of the conjunctiva or the surrounding accessory organs. Ciliary congestion represents a disease of the eye itself, such as keratitis, scleritis, iridocyclitis, and congestive glaucoma. If the blood vessels themselves are diseased or damaged, bleeding may accumulate under the conjunctiva of the eye, which is called subconjunctival hemorrhage and is also a type of ocular congestion. Ocular congestion occurs when the capillaries on the surface of the eye become red, swollen, and congested, and is often caused by insufficient oxygen supply to the cornea or other tissues on the surface of the eye. Eye fatigue and poor dietary habits, especially consuming large amounts of ethanol, can also cause this phenomenon.
[0009] Meibomian gland dysfunction (MGD) is a chronic, diffuse meibomian gland disease characterized by the obstruction of the terminal ducts of the meibomian glands and / or abnormal quality or quantity of meibomian secretion, and is a common ocular surface disease in clinical practice. Obstruction of the meibomian gland ducts can lead to bacterial infection of the ocular surface, resulting in an inflammatory response, ocular irritation symptoms, corresponding changes in the cornea and conjunctiva, and in severe cases, reduced vision and poor prognosis. Mite infection is also a factor in causing MGD, and the main treatments for MGD include eyelid warming, mechanical eyelid care, and pharmaceutical treatments such as antibiotics and anti-inflammatory agents. However, these treatments have certain limitations. Although eyelid warming can dissolve lipids, it cannot address the movement of keratinized material, and temporary visual deterioration due to corneal deformation may occur. Mechanical eyelid care can only provide partial and temporary relief of meibomian gland obstruction, as the force required to remove the obstruction may be large and may cause significant pain to the patient. The topical use of antibiotics and corticosteroids to inhibit bacterial colonization and inflammation of the eyelid margin associated with MGD has been shown to be effective in reducing the symptoms and physical signs of MGD. However, on the one hand, the success of this treatment may not be related to changes in the meibum, and on the other hand, drug intolerance and long treatment times limit the clinical use of oral antibiotics.
[0010] Visual display terminal (VDT), also known as VDT syndrome, refers to a syndrome accompanied by a series of symptoms characteristic of eye fatigue, such as eye fatigue after using a visual display terminal, dry eyes, foreign body sensation in the eyes, heavy eyelids, blurred vision, photophobia and tearing, eye swelling and pain, and eye congestion. According to statistics from the US National Institute for Occupational Safety and Health, about 90% of people who use display devices for an average of more than three hours per day are affected by computer vision syndrome. According to the 42nd "Statistical Report on Internet Development in China", the size of China's network citizens reached 802 million by June 2018, and the average weekly online time of China's network citizens during the same period reached 27.7 hours, which is an increase of 0.7 hours compared to last year, and the Internet penetration rate has increased from 55.8% at the end of last year to 57.7%. With the development of Internet convenience, more and more online education has emerged. A majority of students' parents choose online classes for their children, which gives them more opportunities to use electronic products. These network citizens and students are prone to eye strain, which may further lead to problems such as myopia and MGD. Summary of the Invention [Problem to be solved by the invention]
[0011] In summary, there is an urgent need to develop ophthalmic therapeutic and / or cosmetic products, health care products that have good therapeutic effects, can be used for a long period of time, and have no obvious local or systemic toxicity and side effects for a series of ocular surface diseases and / or conditions, such as ocular surface diseases and / or conditions associated with corneal epithelial injury, ocular surface diseases and / or disorders caused by diabetes, especially ocular surface diseases and / or conditions associated with disease-induced keratopathy, recurrent corneal epithelial erosion, especially surgery-related recurrent corneal epithelial erosion, non-dry eye diseases and / or conditions associated with conjunctivitis (eye redness), ocular congestion, meibomian gland dysfunction, eye fatigue, and myopia. [Means for solving the problem]
[0012] In order to solve the above-mentioned technical problems, the present inventors have carried out thorough research and finally found a technical solution.In particular, the present disclosure provides the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating non-dry eye ocular surface diseases and / or conditions.
[0013] The present disclosure further provides the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating an ocular surface disease and / or condition associated with corneal epithelial injury.
[0014] The present disclosure provides the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions caused by diabetes.
[0015] The present disclosure provides the use of alanyl-glutamine in the manufacture of a medicament for treating, reducing or alleviating ocular surface diseases and / or conditions associated with diabetes-induced keratopathy.
[0016] The present disclosure provides the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with recurrent corneal epithelial erosion.
[0017] The present disclosure provides the use of alanyl-glutamine in the manufacture of a medicament for treating, reducing or alleviating ocular surface diseases and / or conditions associated with surgery-related recurrent corneal epithelial erosion.
[0018] The present disclosure provides the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with tissue repair and healing following ocular trauma and / or surgery.
[0019] The present disclosure further provides the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with conjunctivitis (eye redness).
[0020] The present disclosure provides the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with ocular congestion.
[0021] The present disclosure provides the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with meibomian gland dysfunction.
[0022] The present disclosure further provides the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with eye strain.
[0023] The present disclosure provides the use of alanyl-glutamine in the preparation of a medicament for preventing myopia.
[0024] The present disclosure further provides the use of alanyl-glutamine in the manufacture of a beauty product, health care product for reducing or alleviating eye strain.
[0025] The present disclosure provides the use of alanyl-glutamine in the manufacture of beauty and health care products for preventing myopia.
[0026] The present disclosure further provides the use of alanyl-glutamine in the manufacture of beauty and health care products for the eyes.
[0027] The present disclosure further provides an ophthalmic composition comprising alanyl-glutamine and an ophthalmically acceptable excipient, in the form of an eye drop, suspension, eye ointment, emulsion, eye pad, eye patch, eye mask, eye cream, spray, gel, injectable or indwelling solution.
[0028] The present disclosure provides a method of treating, alleviating or ameliorating non-dry eye ocular surface diseases and / or conditions, ocular surface diseases and / or conditions associated with corneal epithelial injury, ocular surface diseases and / or conditions caused by diabetes, ocular surface diseases and / or conditions associated with diabetic keratopathy, ocular surface diseases and / or conditions associated with recurrent corneal epithelial erosion, ocular surface diseases and / or conditions associated with surgery-related recurrent corneal epithelial erosion, ocular surface diseases and / or conditions associated with tissue repair and healing following ocular trauma and / or surgery, ocular surface diseases and / or conditions associated with conjunctivitis, ocular surface diseases and / or conditions associated with ocular congestion, ocular surface diseases and / or conditions associated with meibomian gland dysfunction, eye strain, ocular surface diseases and / or conditions associated with myopia, comprising administering to a subject a therapeutically effective amount of alanyl-glutamine.
[0029] The present disclosure further provides a method for treating, alleviating or ameliorating non-dry eye ocular surface diseases and / or conditions, ocular surface diseases and / or conditions associated with corneal epithelial injury, ocular surface diseases and / or conditions caused by diabetes, ocular surface diseases and / or conditions associated with diabetic keratopathy, ocular surface diseases and / or conditions associated with recurrent corneal epithelial erosion, ocular surface diseases and / or conditions associated with surgery-related recurrent corneal epithelial erosion, ocular surface diseases and / or conditions associated with tissue repair and healing following ocular trauma and / or surgery, ocular surface diseases and / or conditions associated with conjunctivitis, ocular surface diseases and / or conditions associated with ocular congestion, ocular surface diseases and / or conditions associated with meibomian gland dysfunction, eye strain, ocular surface diseases and / or conditions associated with myopia, comprising administering to a subject a therapeutically effective amount of an ophthalmic composition provided by the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0030] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
[0031] As used herein, the phrase "A and / or B" includes three cases: (1) A; (2) B; and (3) A and B.
[0032] As used herein, a reference to alanyl-glutamine includes alanyl-glutamine itself and pharma- ceutically acceptable salts thereof, unless otherwise indicated or contradicted by context.
[0033] As used herein, the expression "pharmaceutical acceptable salts" includes acid addition salts formed with pharmaceutical acceptable acids, as well as salts formed with pharmaceutical acceptable bases. Pharmaceutically acceptable acids include inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and organic acids such as acetic acid, citric acid, fumaric acid, malic acid, and the like. Salts formed with pharmaceutical acceptable bases include, but are not limited to, ammonium salts, sodium salts, potassium salts, magnesium salts, calcium salts, and the like.
[0034] The inventors of the present invention have unexpectedly discovered that ophthalmic solutions, ophthalmic gels and ophthalmic patches and masks containing alanyl-glutamine can effectively relieve meibomian gland dysfunction, treat conjunctivitis (eye redness), treat corneal ulcers, significantly reduce eye fatigue, prevent myopia, and therefore treat, reduce or ameliorate non-dry eye ocular surface diseases and / or conditions, ocular surface diseases and / or conditions associated with corneal epithelial injury, ocular surface diseases and / or conditions caused by diabetes, particularly ocular surface diseases and / or conditions associated with diabetes induced keratopathy, ocular surface diseases and / or conditions associated with recurrent corneal epithelial erosion and and / or conditions associated with ocular surface diseases and / or conditions, particularly surgery-related recurrent corneal epithelial erosion, treating, alleviating or alleviating ocular surface diseases and / or conditions associated with tissue repair and healing after ocular trauma and / or surgery, treating, alleviating or alleviating ocular surface diseases and / or conditions associated with conjunctivitis (eye redness), treating, alleviating or alleviating ocular surface diseases and / or conditions associated with ocular congestion, treating, alleviating or alleviating ocular surface diseases and / or conditions associated with meibomian gland dysfunction, ocular surface diseases and / or conditions associated with eye strain, and preventing myopia.
[0035] According to one embodiment of the present disclosure, the present disclosure may provide the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating non-dry eye ocular surface diseases and / or conditions.
[0036] According to one embodiment of the present disclosure, the present disclosure may provide the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating an ocular surface disease and / or condition associated with corneal epithelial injury.
[0037] In some embodiments, the "ocular surface disease and / or condition associated with corneal epithelial injury" includes, but is not limited to, keratitis, corneal dystrophies, mechanical corneal epithelial injury, recurrent corneal epithelial erosion, entropion, trichiasis; blepharitis, meibomian gland dysfunction, hypophasis, corneal band degeneration, Salzmann nodular corneal degeneration, posterior contact lens corneal epithelial injury, drug-related corneal epithelial injury, surgery-related corneal epithelial injury, Stevens-Johnson syndrome, Sjogren's syndrome, cicatricial pemphigoid, and the like, which are caused by a variety of factors.
[0038] According to one embodiment of the present disclosure, the present disclosure may provide the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions caused by diabetes.
[0039] According to one embodiment of the present disclosure, the present disclosure may provide the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with diabetes-induced keratopathy.
[0040] In some embodiments, "ocular surface diseases and / or conditions associated with diabetes-induced keratopathy" include, but are not limited to, superficial punctate keratitis, delayed corneal epithelial regeneration, recurrent corneal epithelial erosion, persistent corneal epithelial loss, chronic epitheliitis, superficial corneal ulcer, fibrous keratitis, sterile corneal ulcer, Descemet's membrane folding, corneal hypoesthesia, and corneal edema.
[0041] According to one embodiment of the present disclosure, the present disclosure may provide the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with recurrent corneal epithelial erosion.
[0042] In some embodiments of the present disclosure, the ocular surface disease and / or condition associated with recurrent corneal epithelial erosion may be surgery-related or non-surgical related.
[0043] According to one embodiment of the present disclosure, the present disclosure may provide the use of alanyl-glutamine in the manufacture of a medicament for treating, reducing or alleviating ocular surface diseases and / or conditions associated with surgery-related recurrent corneal epithelial erosion.
[0044] In some embodiments, "ocular surface diseases and / or conditions associated with surgery-associated recurrent corneal epithelial erosion" include, but are not limited to, superficial punctate keratitis, delayed corneal epithelial regeneration, recurrent corneal epithelial erosion, persistent corneal epithelial loss, chronic epitheliitis, superficial corneal ulcer, fibrous keratitis, sterile corneal ulcer, Descemet's membrane folding, corneal hypoesthesia, and corneal edema.
[0045] According to one embodiment of the present disclosure, the present disclosure may provide the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating an ocular surface disease and / or condition associated with tissue repair and healing following ocular trauma and / or surgery.
[0046] In some embodiments, "ocular surface diseases and / or conditions associated with tissue repair and healing following ocular trauma and / or surgery" include, but are not limited to, ocular tissue injury and ocular foreign body sensation following cataract surgery, ocular tissue injury and ocular foreign body sensation following glaucoma surgery, ocular wounds following ocular trauma and / or surgery, injury caused by mechanical ocular injury, injury caused by intraocular foreign bodies, injury caused by ocular chemical burns, injury caused by ocular burns, injury caused by radiation-induced ocular injury, injury caused by photoinjury, injury caused by ionizing radiation and microwaves, injury caused by ocular electric shock and stress-induced ocular injury.
[0047] According to one embodiment of the present disclosure, the present disclosure may provide the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with conjunctivitis (eye redness).
[0048] In some embodiments, "ocular surface diseases and / or conditions associated with conjunctivitis (eye redness)" include, but are not limited to, bacterial conjunctivitis, viral conjunctivitis, chlamydial conjunctivitis, inclusion conjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis, seasonal allergic conjunctivitis, giant papillary conjunctivitis, phlyctenular keratoconjunctivitis, autoimmune conjunctivitis, conjunctival tumors, and pterygium.
[0049] According to one embodiment of the present disclosure, the present disclosure may provide the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with ocular congestion.
[0050] In some embodiments, "ocular surface diseases and / or conditions associated with ocular congestion" include, but are not limited to, bacterial conjunctivitis, viral conjunctivitis, chlamydial conjunctivitis, inclusion conjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis, seasonal allergic conjunctivitis, acute iridocyclitis, keratitis, subconjunctival hemorrhage, giant papillary conjunctivitis, phlyctenular keratoconjunctivitis, autoimmune conjunctivitis, conjunctival tumors, pterygium, congestion caused by ocular surgery such as cataract and glaucoma surgery and laser myopia surgery.
[0051] According to one embodiment of the present disclosure, the present disclosure may provide the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with meibomian gland dysfunction.
[0052] In some embodiments, "ocular surface diseases and / or conditions associated with meibomian gland dysfunction" include, but are not limited to, blepharitis, meibomian gland dysfunction, and conjunctival congestion due to meibomian gland dysfunction.
[0053] According to one embodiment of the present disclosure, the present disclosure may provide the use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with eye strain.
[0054] In some embodiments, "ocular surface diseases and / or conditions associated with eye strain" include, but are not limited to, conjunctivitis, meibomian gland dysfunction, blepharitis, conjunctivitis, or ptosis.
[0055] According to one embodiment of the present disclosure, the present disclosure may provide a use of alanyl-glutamine in the preparation of a medicament for preventing myopia.
[0056] According to one embodiment of the present disclosure, the present disclosure may provide the use of alanyl-glutamine in the manufacture of beauty and health care products for reducing or alleviating eye fatigue.
[0057] According to one embodiment of the present disclosure, the present disclosure may provide a use of alanyl-glutamine in the manufacture of beauty and health care products for preventing myopia.
[0058] As used herein, a "cosmetic product" may take the form of, including, but not limited to, eye creams, eye gels, eye sprays, eye patches, eye pads, eye masks, and the like.
[0059] As used herein, "health care products" may include, but are not limited to, "disinfectant product numbers," "health product numbers," and "medical device product numbers" eye drops, eye washes, eye gels, eye sprays, eye patches, eye pads, eye masks, and the like.
[0060] According to one embodiment of the present disclosure, the present disclosure may provide the use of alanyl-glutamine in the manufacture of beauty and health care products for eyes.
[0061] According to one embodiment of the present disclosure, the present disclosure may provide an ophthalmic composition comprising alanyl-glutamine and an ophthalmically acceptable excipient, the ophthalmic composition being in the form of an eye drop, suspension, eye ointment, emulsion, eye pad, eye patch, eye mask, eye cream, spray, gel, injectable or indwelling solution.
[0062] In some embodiments, the ophthalmic composition may be a pharmaceutical product, a cosmetic product, or a health care product.
[0063] In some embodiments, the eye drop may be an ophthalmic solution or an ophthalmic suspension.
[0064] In some embodiments, the ophthalmic composition is in isotonic or hypotonic form.
[0065] As used herein, "isotonic" refers to the osmotic pressure of the ophthalmic pharmaceutical composition being the same or substantially the same as the osmotic pressure of ocular surface epithelial cells. As used herein, "hypotonic" refers to the osmotic pressure of the ophthalmic pharmaceutical composition being lower than the osmotic pressure of ocular surface epithelial cells.
[0066] In some embodiments, the concentration of alanyl-glutamine in the ophthalmic composition is between 0.05% w / w and 10% w / w.
[0067] In some embodiments, the concentration of alanyl-glutamine in the ophthalmic composition is between 0.05% w / w and 9% w / w, between 0.05% w / w and 8% w / w, between 0.05% w / w and 7% w / w, between 0.05% w / w and 6% w / w, between 0.05% w / w and 5% w / w, between 0.05% w / w and 4% w / w, between 0.05% w / w and 3% w / w, between 0.05% w / w and 2% w / w, between 0.05% w / w and 1% w / w, or between 0.05% w / w and 0.1% w / w.
[0068] In some embodiments, the ophthalmically acceptable excipient comprises one or more of an osmolality adjusting agent, a bacteriostat, a viscosity increasing agent, a pH adjusting agent, a stabilizer, a surfactant, a humectant, and the like.
[0069] In some embodiments, the osmotic modifier is selected from one or more of laurocapram, sodium chloride, potassium chloride, boric acid, borax, sodium sulfate, potassium sulfate, sodium nitrate, potassium nitrate, sodium acetate, mannitol, glycerol, propylene glycol, sorbitol, 2-(4-n-octylphenylethyl)-2-aminopropylene glycol hydrochloride, glucose, sucrose, fructose and lactose. In some embodiments, the osmotic modifier is laurocapram, boric acid, glycerin, propylene glycol, and / or sodium chloride.
[0070] In some embodiments, the bacteriostatic agent is selected from one or more of benzalkonium chloride, benzalkonium bromide, quaternium salt-73, chlorhexidine acetate, glucose chlorhexidine, trichloro tert-butanol, phenoxyethanol, methyl hydroxybenzoate, ethyl hydroxybenzoate, and propyl hydroxybenzoate. In some embodiments, the bacteriostatic agent is benzalkonium chloride, quaternium-73, phenoxyethanol, and / or ethyl hydroxybenzoate.
[0071] In some embodiments, the thickening agent is selected from one or more of sodium hyaluronate, triethanolamine, carbopol, sodium carboxymethylcellulose, methylcellulose, polyethylene glycol, polyvinyl alcohol and povidone. In some embodiments, the thickening agent is sodium hyaluronate, carbopol 940, and / or triethanolamine.
[0072] In some embodiments, the pH adjuster is selected from one or more of sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, boric acid, borax, acetic acid, sodium acetate, citric acid, sodium citrate, tartaric acid, sodium tartrate, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, potassium hydroxide, hydrochloric acid and phosphoric acid.In some embodiments, the pH adjuster is selected from one or more of sodium carbonate, sodium bicarbonate and sodium hydroxide.In some embodiments, the pH adjuster is sodium hydroxide.
[0073] In some embodiments, the stabilizer is selected from one or more of edetate disodium, edetate calcium disodium, edetate dipotassium, edetate diamine, 2,3-dimercapto-1-propanesulfonic acid, dimercaptosuccinic acid, dimercaprol, deferoxamine mesylate, α-lipoic acid, nitrilotriacetate, penicillamine, ethylene glycol dimethacrylate, sodium oleate, anhydrous sodium sulfite, sodium ascorbate, deferoxamine, malic acid, citric acid, succinic acid, and the sodium, calcium and magnesium salts of malic acid, citric acid and succinic acid.In some embodiments, the stabilizer is edetate disodium.
[0074] In some embodiments, the surfactant is selected from one or more of poloxamer, sodium dodecyl sulfate, Tween-20, Tween-40, Tween-60, Tween-65, Tween-80, Tween-85, lecithin, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, polyvinylpyrrolidone, polyethylene glycol, and polyethylene glycol 15-hydroxystearate. In some embodiments, the surfactant is selected from Tween-80.
[0075] In some embodiments, the humectant is selected from one or more of glycerol, butanediol, polyethylene glycol, propylene glycol, hexanediol, xylitol, polypropylene glycol, sorbitol, sodium pyrrolidone carboxylate, sodium lactate, urea, hydroxyethyl urea, methyl glucose polyether, chitin derivatives, trehalose, tremella fuciformis polysaccharide, sodium hyaluronate, panthenol, ceramides, natural plant extracts, and the like.
[0076] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, alleviating or ameliorating non-dry eye ocular surface diseases and / or conditions, ocular surface diseases and / or conditions associated with corneal epithelial injury, ocular surface diseases and / or conditions caused by diabetes, ocular surface diseases and / or conditions associated with diabetic keratopathy, ocular surface diseases and / or conditions associated with recurrent corneal epithelial erosion, ocular surface diseases and / or conditions associated with surgery-related recurrent corneal epithelial erosion, ocular surface diseases and / or conditions associated with tissue repair and healing following ocular trauma and / or surgery, ocular surface diseases and / or conditions associated with conjunctivitis, ocular surface diseases and / or conditions associated with ocular congestion, ocular surface diseases and / or conditions associated with meibomian gland dysfunction, eye strain, ocular surface diseases and / or conditions associated with myopia, comprising administering to a subject a therapeutically effective amount of alanyl-glutamine.
[0077] As used herein, the phrase "subject" refers to a mammal, a primate (e.g., a human, male or female), a dog, a rabbit, a guinea pig, a rat, a mouse, etc. In some embodiments, the subject is a primate. In some embodiments, the subject is a human.
[0078] As used herein, the phrase "therapeutically effective amount" refers to an amount of an alanyl-glutamine or ophthalmic composition of the present disclosure that can elicit a biological or medical response in a subject, such as an amount that treats, alleviates or ameliorates a disease and / or condition.
[0079] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, alleviating or ameliorating a non-dry eye ocular surface disease and / or condition, the method comprising administering to a subject a therapeutically effective amount of alanyl-glutamine.
[0080] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, reducing or alleviating an ocular surface disease and / or condition associated with corneal epithelial damage, the method comprising administering to a subject a therapeutically effective amount of alanyl-glutamine.
[0081] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, reducing or alleviating ocular surface diseases and / or conditions caused by diabetes, the method comprising administering to a subject a therapeutically effective amount of alanyl-glutamine.
[0082] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, reducing or alleviating ocular surface diseases and / or conditions associated with diabetes-induced keratopathy, the method comprising administering to a subject a therapeutically effective amount of alanyl-glutamine.
[0083] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, reducing or alleviating an ocular surface disease and / or condition associated with recurrent corneal epithelial erosion, the method comprising administering to a subject a therapeutically effective amount of alanyl-glutamine.
[0084] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, reducing or alleviating ocular surface diseases and / or conditions associated with surgery-related recurrent corneal epithelial erosion, the method comprising administering to a subject a therapeutically effective amount of alanyl-glutamine.
[0085] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, alleviating or ameliorating an ocular surface disease and / or condition associated with tissue repair and healing following ocular trauma and / or surgery, the method comprising administering to a subject a therapeutically effective amount of alanyl-glutamine.
[0086] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with conjunctivitis, the method comprising administering to a subject a therapeutically effective amount of alanyl-glutamine.
[0087] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, alleviating or ameliorating an ocular surface disease and / or condition associated with ocular congestion, the method comprising administering to a subject a therapeutically effective amount of alanyl-glutamine.
[0088] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, alleviating or ameliorating an ocular surface disease and / or condition associated with meibomian gland dysfunction, the method comprising administering to a subject a therapeutically effective amount of alanyl-glutamine.
[0089] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with eye strain, the method comprising administering to a subject a therapeutically effective amount of alanyl-glutamine.
[0090] According to one embodiment of the present disclosure, the present disclosure may provide a method for preventing myopia, the method comprising administering to a subject a therapeutically effective amount of alanyl-glutamine.
[0091] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, alleviating or ameliorating non-dry eye ocular surface diseases and / or conditions, ocular surface diseases and / or conditions associated with corneal epithelial injury, ocular surface diseases and / or conditions caused by diabetes, ocular surface diseases and / or conditions associated with diabetic keratopathy, ocular surface diseases and / or conditions associated with recurrent corneal epithelial erosion, ocular surface diseases and / or conditions associated with surgery-related recurrent corneal epithelial erosion, ocular surface diseases and / or conditions associated with tissue repair and healing following ocular trauma and / or surgery, ocular surface diseases and / or conditions associated with conjunctivitis, ocular surface diseases and / or conditions associated with ocular congestion, ocular surface diseases and / or conditions associated with meibomian gland dysfunction, eye strain, ocular surface diseases and / or conditions associated with myopia, comprising administering to a subject an ophthalmic composition of the present disclosure.
[0092] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, alleviating or ameliorating a non-dry eye ocular surface disease and / or condition, the method comprising administering to a subject a therapeutically effective amount of an ophthalmic composition of the present disclosure.
[0093] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, reducing or alleviating an ocular surface disease and / or condition associated with corneal epithelial damage, the method comprising administering to a subject a therapeutically effective amount of an ophthalmic composition of the present disclosure.
[0094] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, reducing or alleviating ocular surface diseases and / or conditions caused by diabetes, the method comprising administering to a subject a therapeutically effective amount of an ophthalmic composition of the present disclosure.
[0095] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, reducing or alleviating ocular surface diseases and / or conditions associated with diabetes-induced keratopathy, the method comprising administering to a subject a therapeutically effective amount of an ophthalmic composition of the present disclosure.
[0096] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, reducing or alleviating ocular surface diseases and / or conditions associated with recurrent corneal epithelial erosion, the method comprising administering to a subject a therapeutically effective amount of an ophthalmic composition of the present disclosure.
[0097] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, reducing or alleviating ocular surface diseases and / or conditions associated with surgery-related recurrent corneal epithelial erosion, the method comprising administering to a subject a therapeutically effective amount of an ophthalmic composition of the present disclosure.
[0098] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, alleviating or ameliorating an ocular surface disease and / or condition associated with tissue repair and healing following ocular trauma and / or surgery, the method comprising administering to a subject a therapeutically effective amount of an ophthalmic composition of the present disclosure.
[0099] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with conjunctivitis, the method comprising administering to a subject a therapeutically effective amount of an ophthalmic composition of the present disclosure.
[0100] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, alleviating or ameliorating an ocular surface disease and / or condition associated with ocular congestion, the method comprising administering to a subject a therapeutically effective amount of an ophthalmic composition of the present disclosure.
[0101] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, alleviating or ameliorating an ocular surface disease and / or condition associated with meibomian gland dysfunction, the method comprising administering to a subject a therapeutically effective amount of an ophthalmic composition of the present disclosure.
[0102] According to one embodiment of the present disclosure, the present disclosure may provide a method of treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with eye fatigue, the method comprising administering to a subject a therapeutically effective amount of an ophthalmic composition of the present disclosure.
[0103] According to one embodiment of the present disclosure, the present disclosure may provide a method for preventing myopia, the method comprising administering to a subject a therapeutically effective dose of an ophthalmic composition of the present disclosure.
[0104] The technical solutions of the present disclosure will be more clear and clearly described by the description in combination with the examples. It should be understood that these examples are merely for illustrative purposes and are not intended to limit the scope of protection of the present disclosure. The scope of protection of the present disclosure is defined only by the claims. EXAMPLES
[0105] Unless otherwise stated, the reagents and instruments used in the following examples are conventional products available on the market.Unless otherwise stated, the experiments are carried out under conventional conditions or under conditions recommended by the manufacturer.The "L-alanyl-L-glutamine" used in the examples, i.e., alanyl-glutamine itself, was available from Hubei Bioche Pharmaceutical Technology Co., Ltd. The 0.25% chloramphenicol eye drops used in the examples were available from Shandong Bausch & Lamb Freda Pharmaceutical Co., Ltd., the 0.1% diclofenac sodium eye drops were available from Shenyang Xingqi Eye Medicine Co., Ltd., the 0.1% pranoprofen eye drops were available from Guangdong Zhongsheng Pharmaceutical Co., Ltd., the sodium hyaluronate eye drops were available from Zhejiang Jianfeng Pharmaceutical Co., Ltd., the Zhenshiming eye drops were available from Zhenshiming Pharmaceutical Co., Ltd., and the polyvinyl alcohol eye drops were available from Hubei Yuanda Tiantianming Pharmaceutical Co., Ltd.
[0106] Example 1 Preparation of Alanyl-Glutamine-Containing Ophthalmic Solutions, Ophthalmic Creams, and Ophthalmic Gels Ophthalmic solutions, creams, and gels containing alanyl-glutamine were prepared according to the following compositions and preparation methods:
[0107] [Table 1]
[0108] Method for preparing ophthalmic solution: (1) Boric acid, sodium chloride, benzalkonium chloride, and disodium edetate were weighed out in the ratios shown in Table 1, and 80% water for injection was added thereto and dissolved under stirring. (2) L-alanyl-L-glutamine was added in the ratio shown in Table 1 and dissolved under stirring. The pH was adjusted to 6.0 with 0.5 mol / L sodium hydroxide under stirring. (3) The remaining volume was made up with water for injection, and the resulting mixture was filtered in two stages through 0.45 μm and 0.22 μm sterile filters, respectively, and then filled into eye drop bottles.
[0109] The solution vehicle was prepared according to the composition and method described above. The only difference between the solution vehicle and the ophthalmic solution was: L-alanyl-L-glutamine was replaced with an equal amount of water.
[0110] [Table 2]
[0111] Method for preparing ophthalmic cream: (1) White petrolatum, liquid paraffin, stearic acid and glyceryl monostearate were weighed out in the ratios shown in Table 2, added to an oil phase tank, heated to 75 to 85°C to dissolve, stirred evenly, and used as the oil phase. (2) Purified water, methyl hydroxybenzoate, sodium lauryl sulfate, glycerin, sodium hyaluronate, and disodium edetate were weighed out in the ratios shown in Table 2, added to an aqueous phase tank, heated to 75 to 85°C, stirred to dissolve, and used as the aqueous phase. (3) L-alanyl-L-glutamine was added to the aqueous phase in the ratio shown in Table 2 and dissolved. (4) The oil phase liquid was added to the emulsification tank, stirring was started, and then the water phase liquid was added to the emulsification tank. The mixture was emulsified at 65-75°C for 20-30 minutes, cooled to less than 35°C, and stirring was stopped to obtain a cream.
[0112] A cream vehicle was prepared according to the composition and method described above. The only difference between the cream vehicle and the ophthalmic cream was: L-alanyl-L-glutamine was replaced with an equal amount of water.
[0113] [Table 3]
[0114] Method for preparing ophthalmic gel: (1) L-alanyl-L-glutamine was dissolved in 50 ml of purified water to obtain an aqueous L-alanyl-L-glutamine solution. (2) Carbopol 940 and glycerin were thoroughly mixed and added to the aqueous L-alanyl-L-glutamine solution obtained in (1) to thoroughly swell the Carbopol. (3) Ethyl hydroxybenzoate was dissolved in ethanol, mixed with propylene glycol, stirred and slowly added to the solution of (2). (4) Tween-80 and triethanolamine were dissolved in the remaining amount of purified water, added to the solution of (3) under stirring, and stirred until homogenous to obtain a gel.
[0115] The gel vehicle was prepared according to the composition and method described above. The only difference between the cream gel and the ophthalmic gel was: L-alanyl-L-glutamine was replaced with an equal amount of water.
[0116] Example 2 Irritation test (1) Skin irritation test Thirty-six healthy New Zealand rabbits were randomly divided into six groups, six rabbits per group, half male and half female, for single-dose and multiple-dose skin irritation experiments, each experiment divided into two groups, i.e., intact skin group and injured skin group, and all comparisons were performed using the homobody left-right self-control method. On the back of New Zealand rabbits, two sites (approximately 3.0 cm × 3.0 cm area) on the back of each rabbit were depilated using 8.0% sodium sulfide aqueous solution, and New Zealand rabbits with erythema, edema or injury in the depilated area were excluded. The injured skin model was established 24 hours after depilation: first, the depilated area was washed with warm water and disinfected with iodophor, and then a "#" symbol was lightly marked on it using a sterile needle, causing skin injury with a slight degree of focal bleeding on the skin; the intact skin model was established: an intact, uninjured, and abnormal skin area was selected.
[0117] 10% ophthalmic solution and solution vehicle, 10% ophthalmic cream and cream vehicle, 10% ophthalmic gel and gel vehicle were evenly applied to the depilated area of different New Zealand rabbits (injured skin group and intact skin group), the surface was covered with thin gauze, bandaged and fixed with non-irritating breathable non-woven tape. Single-dose skin irritation experiment (one dose) and multiple-dose skin irritation experiment (once a day, 14 consecutive days of administration). Specific steps: The test substances were contacted with the skin for 24 hours, and the skin response (erythema, edema) of different sites to the test drug was observed and recorded with the naked eye every day, 0.5 hours and 1 hour before administration, respectively, and after drug removal. 72 hours after the last drug removal, all animals were euthanized, and the skin tissues from the administration sites were taken for histopathological examination. Statistical scoring was performed with reference to the skin irritation response scoring standard, and the intensity of skin irritation was evaluated based on the calculated score.
[0118] [Table 4]
[0119] [Table 5]
[0120] Under the conditions of this study, single application doses were administered to intact and injured skin of conventional New Zealand rabbits, and the mean irritation score at the application site as observed with the naked eye was 0, indicating no irritation. Specific results are shown in Table 6.
[0121] Repeated application was performed once daily for 14 consecutive days on intact and injured skin of conventional New Zealand rabbits. The mean irritation scores of all application sites observed with the naked eye were 0, indicating no irritation; the mean irritation scores of histopathological examination were 0, indicating no irritation. Specific results are shown in Table 7.
[0122] [Table 6]
[0123] [Table 7]
[0124] (2) Skin allergy test Fifty-six healthy guinea pigs were randomly divided into seven groups, namely, 10% ophthalmic solution and solution vehicle, 10% ophthalmic cream and cream vehicle, 10% ophthalmic gel and gel vehicle, and positive control group, with eight animals in each group, half male and half female. Hair removal was performed on the backs of the guinea pigs using 10% aqueous sodium sulfide solution in ethanol, and the depilated area was approximately 3.0 cm × 3.0 cm. 24 hours after depilation, subjects without skin lesions were selected and selected for the experiment. The administration method was the same as that of the single-dose skin irritation test. In the positive control group, 0.2 ml of 1% 2,4-dinitrochlorobenzene was applied to the depilated area of each guinea pig for 6 hours, and then washed off with warm water. The same method was used to sensitize again on the 7th and 14th days, for a total of three sensitizations. 14 days after the last sensitization of the test substance, the test substance (positive control group: 0.1% 2,4-dinitrochlorobenzene) was applied again to the depilated area of the corresponding guinea pig group. After 6 hours, the test site was washed with warm water, and the skin allergic response was observed immediately and recorded once 24 hours, 48 hours, and 72 hours after washing the test substance, and the allergic response was scored according to the skin allergy response scoring standard (Table 4). The sensitization intensity of the test substance was evaluated based on the sensitization incidence, where the average score=(total score of erythema formation+total score of edema formation) / total number of animals, and the sensitization rate%=(number of animals with erythema, edema, or systemic allergic response / total number of test animals)×100%.
[0125] [Table 8]
[0126] No obvious abnormalities were generally observed in all animals during the study. In eight cases (8 / 8) in the positive control group, mild to severe symptoms of erythema and edema were observed at the administration site 1 hour and 24 hours after each sensitization and drug removal from the animals, and white to dark red crusts of various sizes could be seen at the administration site of the animals from the fourth day of sensitization to the seventh day after the last sensitization. The incidence of sensitization was 100%, the grade was level V, and the intensity of sensitization was extreme sensitization.
[0127] For the 10% ophthalmic solution and solution vehicle groups, 10% ophthalmic cream and cream vehicle groups, and 10% ophthalmic gel and gel vehicle groups: 1 hour, 24 hours, and 48 hours after challenge administration and drug removal, the skin at the administration site of 8 animals (8 / 8) showed no signs of allergic response. The mean score was 0, the sensitization incidence was 0%, the grade was Level I, and the sensitization intensity was weak sensitization. The specific results are shown in Table 9.
[0128] [Table 9]
[0129] Example 3 Testing for efficacy in reducing infectious acute conjunctivitis (1) Study on treatment of severe acute infectious conjunctivitis Test group: 24 patients with comparable conditions, 13 males and 11 females, ages 8-75 years, with severe conditions (patients had redness in both eyes, redness and swelling of eyelids, photophobia, itchy eyes, burning sensation in eyes, tearing or lacrimation, and a lot of eye discharge in the eyes) were selected. The 0.05% ophthalmic solution prepared in Example 1 was instilled into the eyes three times a day for five consecutive days.
[0130] Control group: 23 patients with comparable condition, 12 males and 11 females, age 8-73 years, with severe condition (patients had redness in both eyes, redness and swelling of eyelids, photophobia, itchy eyes, burning sensation in eyes, tearing or lacrimation, and a lot of eye discharge in eyes) were selected. 0.25% chloramphenicol eye drops were instilled three times a day for five consecutive days.
[0131] The therapeutic effect was observed after 5 days, and a follow-up visit was carried out after 15 days to observe whether recurrence occurred. The cure rate and recurrence rate of the test group compared with the control group are shown in Table 10.
[0132] [Table 10]
[0133] The results showed that: for infectious acute conjunctivitis with severe condition, the cure rate of the ophthalmic solution of Example 1 was significantly higher than that of 0.25% chloramphenicol eye drops, and the recurrence rate was significantly lower than that of 0.25% chloramphenicol eye drops.
[0134] (2) Study on the treatment of moderately severe infectious acute conjunctivitis Test group: 25 patients with comparable conditions, 13 males and 12 females, ages 8-75 years, with moderate conditions (patients had redness in both eyes, redness and swelling of eyelids, photophobia, itchy eyes, and burning sensation in eyes) were selected. The 0.05% ophthalmic solution prepared in Example 1 was instilled into the eyes three times a day for five consecutive days.
[0135] Control group: 24 patients with comparable condition, 12 males and 12 females, age 8-73 years, with moderate condition (patients had redness in both eyes, redness and swelling of eyelids, photophobia, itchy eyes, and burning sensation in eyes) were selected. 0.25% chloramphenicol eye drops were instilled three times a day for five consecutive days.
[0136] The therapeutic effect was observed after 5 days, and a follow-up visit was carried out after 15 days to observe whether recurrence occurred. The cure rate and recurrence rate of the test group compared with the control group are shown in Table 11.
[0137] [Table 11]
[0138] The results showed that for infectious acute conjunctivitis with moderate severity, the cure rate of the ophthalmic solution of Example 1 was significantly higher than that of 0.25% chloramphenicol eye drops, and the recurrence rate was significantly lower than that of 0.25% chloramphenicol eye drops.
[0139] In summary, compositions containing alanyl-glutamine can effectively treat, reduce or alleviate infectious acute conjunctivitis.
[0140] Example 4 Testing for efficacy in reducing eye congestion (1) Eye congestion caused by cataract surgery Test group: 19 patients with all scores (+++) for conjunctival congestion after cataract surgery were selected; 7 males and 12 females, aged 62-77 years. The 0.05% ophthalmic solution prepared in Example 1 was instilled into the eyes at 1 drop / eye / time, 3 times / day, 4 hours apart for 3 consecutive days.
[0141] Control group: 17 patients with all scores (+++) on conjunctival congestion after cataract surgery were selected; 6 males and 11 females, aged 62-77 years. 0.1% diclofenac sodium eye drops were administered, 1 drop / eye / time, 3 doses / day, 3 consecutive days, with an interval of 4 hours between each dose.
[0142] The conjunctival congestion of the two groups of patients was observed for 30 minutes after the second administration of eye drops on the third day. The grading standard of conjunctival congestion is classified as follows: (1) no congestion (-); (2) mild congestion (+): congestion is limited to the palpebral fissure, and the blood vessels are bright red; (3) moderate congestion (++): congestion can obviously reach the fornix, and the blood vessels are clogged and appear dark red; (4) severe congestion (+++): the whole conjunctiva is diffusely congested, and the blood vessels are reddish purple and unclear.
[0143] The results of comparing the conjunctival congestion of patients between the two groups are shown in Table 12. Using the MW U test for the statistics of independent samples of the two groups, the Mann-Whitney U value was 97.000, P=0.042<0.05; the results showed that the ophthalmic solution of Example 1 was significantly better than 0.1% diclofenac sodium eye drops in relieving ocular congestion caused by cataract surgery, and the ophthalmic solution of Example 1 has significant clinical application value after cataract surgery.
[0144] [Table 12]
[0145] (2) Eye congestion caused by other types of diseases Patients with a score of (+++) for conjunctival congestion caused by reasons such as immune-mediated ocular surface disease and inflammation were selected.
[0146] Test group: 23 subjects, 12 males and 11 females, aged 8 to 65 years. The 0.05% ophthalmic solution prepared in Example 1 was instilled into the eyes at 1 drop / eye / time, 3 times / day, with 4-hour intervals between each administration, for 3 consecutive days.
[0147] Control group: 24 cases, 13 males and 11 females, aged 8-63 years, were administered 0.1% pranoprofen eye drops, 1 drop / eye / time, 3 doses / day, 3 consecutive days, with 4-hour intervals between each dose.
[0148] The conjunctival congestion of the two groups of patients was observed for 30 minutes after the second administration of eye drops on the third day. The grading standard of conjunctival congestion is classified as follows: (1) no congestion (-); (2) mild congestion (+): congestion is limited to the palpebral fissure, and the blood vessels are bright red; (3) moderate congestion (++): congestion can obviously reach the fornix, and the blood vessels are clogged and appear dark red; (4) severe congestion (+++): the whole conjunctiva is diffusely congested, and the blood vessels are reddish purple and unclear.
[0149] The results of comparing the conjunctival congestion of patients between the two groups are shown in Table 13. Using the MW U test for the statistics of independent samples of the two groups, the Mann-Whitney U value was 182.500, P=0.031<0.05; the results showed that the ophthalmic solution of Example 1 had a significantly better therapeutic effect than 0.1% pranoprofen eye drops on ocular congestion caused by other diseases, and the ophthalmic solution of Example 1 also has significant clinical application value for ocular congestion caused by other types of diseases.
[0150] [Table 13]
[0151] (3) Eye congestion caused by lifestyle or eye make-up Subjects with normal mild eye congestion or mild eye congestion without obvious pathogenic factors, or mild eye congestion caused by eye make-up were recruited (if patients had mild congestion in both eyes, the right eye of each patient was selected as the observation eye).
[0152] Test group: 60 subjects, 15 males and 45 females, aged 20 to 50 years. The 0.05% ophthalmic solution prepared in Example 1 was instilled into the eyes at 1 drop / eye / time, 3 times / day, with 4-hour intervals between each administration, for 3 consecutive days.
[0153] Control group: 60 subjects, 16 males and 44 females, aged 19-50 years, were administered sodium hyaluronate eye drops, 1 drop / eye / time, 3 times / day, 3 consecutive days, with 4-hour intervals between each time.
[0154] The conjunctival congestion of the subjects in the two groups was observed 10 and 30 minutes after the first administration of eye drops on day 1, and 30 minutes after the first administration of eye drops on days 2 and 3. The grading standard of conjunctival congestion is classified as follows: (1) no congestion (-); (2) mild congestion (+): congestion is limited to the palpebral fissure, and the blood vessels are bright red; (3) moderate congestion (++): congestion can clearly reach the fornix, and the blood vessels are clogged and appear dark red; (4) severe congestion (+++): the whole conjunctiva is diffusely congested, and the blood vessels are reddish purple and unclear.
[0155] The results of comparing the conjunctival congestion of patients between the two groups are shown in Table 14. At 10 minutes and 30 minutes after the first administration, the effective rates of the test group were 65% and 86.3%, respectively, and the effective rates of the control group were 23.3% and 28.3%, respectively. There was a significant difference in the effective rates between the two groups (P<0.05 or P<0.01). At 30 minutes after administration on the second and third days, the effective rates of the test group were 98.3% and 98.3%, respectively, and the effective rates of the control group were 45% and 55%, respectively. There was a significant difference in the effective rates between the two groups (P<0.01). It is suggested that the ophthalmic solution of Example 1 has significant effect and significant clinical application value in treating ordinary mild ocular congestion or mild ocular congestion without obvious pathogenic factors, or mild ocular congestion caused by eye makeup.
[0156] [Table 14]
[0157] [Table 15]
[0158] Example 5 A study on the effectiveness of treatments for corneal ulcers In vitro model of corneal ulcer Rabbit corneas were collected, cut into small pieces, and 5-10 times the volume of 5% Triton solution was added, homogenized until no clumped particles were present, and then centrifuged at 3000r / min for 10 minutes to remove the supernatant. 5ml of the supernatant was removed and mixed with 5ml of complete Freund's adjuvant to prepare a mixed solution for later use.
[0159] Mice with SPF grade ICR were divided into normal, immune, and cyclophosphamide groups, with 10 mice per group. The normal group received subcutaneous injections of 0.5 ml saline per mouse; each mouse in the immune and cyclophosphamide groups received subcutaneous injections of mixed solution + saline, mixed solution + cyclophosphamide 300 mg / kg, respectively, with no overlapping injection sites; injections were performed once every other day, for a total of 10 times. Three days after the final injection, the mice were euthanized using bloodletting, and the eyeballs were removed and cut into small pieces under aseptic conditions. At the same time, leukocytes isolated from the cornea and autologous blood were co-cultured in 24-well culture plates. The corneas in the normal group, the corneas in the immune group, the corneas in the cyclophosphamide group, and the corneas in the immune group were administered with 0.05% ophthalmic solution as described in Example 1, and five replicate wells were set up for each cornea, and the solution was replaced once every 24 hours to observe the growth of corneal tissue cells.
[0160] Test results The growth rates of corneal cells in the normal group at 72 hours and 120 hours were 24.0% and 36.0%, while the growth rates of corneal cells in the immune group were both 0%. After administration of 0.05% ophthalmic solution, the growth rates of corneal cells at 72 hours and 120 hours were 8% and 14%, with significant differences (P<0.01) compared with the immune group, thus proving that the ophthalmic solution inhibits the immune response of cell growth and promotes the growth of corneal cells. Therefore, the composition containing alanyl-glutamine can effectively treat, reduce or alleviate corneal epithelial injury, corneal ulcer, recurrent corneal epithelial erosion, and diabetic keratopathy.
[0161] [Table 16]
[0162] Example 6 Testing for effectiveness in reducing eye strain (1) Test for relieving symptoms of eye strain The relief of eye fatigue symptoms was observed 30 minutes after using the 0.05% ophthalmic cream, 0.05% ophthalmic gel, 0.05% ophthalmic solution and Zhenshiming eye drops prepared in Example 1 of the present disclosure, and scored by experienced doctors to calculate the total effective rate. The calculation formula is as follows: Symptom score improvement rate = (score before treatment - score after treatment) / score before treatment x 100% Significantly effective: symptom score improvement rate is greater than 80%; Effective: symptom score improvement of >40%; Ineffective: symptom score improvement of less than 40 points, or no change, or worsening; Total effective rate = (significantly effective + effective) number of people / total number of people x 100%
[0163] The total number of people in the study was 107, including 26 in the 0.05% ophthalmic cream group, 28 in the 0.05% ophthalmic gel group, 28 in the 0.05% ophthalmic solution group, and 25 in the Zhenshiming eye drops group. The specific results are shown in Table 16.
[0164] [Table 17]
[0165] From the above experimental results, it can be seen that the ophthalmic cream, ophthalmic gel and ophthalmic solution of Example 1 are significantly better than Zhenshiming eye drops in relieving the symptoms of eye fatigue.
[0166] (2) Testing duration of photopic vision The duration of photopic vision was measured with reference to the "Method for Assessment of Asthenopia Relief Function" in the "Notice on the Issuance of 9 Health Function Assessment Methods including the Method for Assessment of Antioxidant Function, Health Food and Cosmetics Supervision Department, State Food and Drug Administration (2012) No. 107." This study adopted a survey method to compare before and after the self-control treatment, and the results are shown in Table 17.
[0167] [Table 18]
[0168] Table 17 shows that after using the ophthalmic cream, ophthalmic gel and ophthalmic solution of Example 1, the duration of photopic vision was significantly improved compared with before the self-control test (p<0.05), and the increase rates were all greater than 20%, and the effect was significantly better than Zhenshiming eye drops.
[0169] Combined with the significant effects of ophthalmic creams, ophthalmic gels and ophthalmic solutions in relieving symptoms of eye strain and duration of photopic vision, the composition containing alanyl-glutamine was effectively proven to have the function of relieving eye strain.
[0170] Example 7 A study on the therapeutic effects of ocular discomfort mainly caused by foreign body sensation A foreign body sensation score was used as the criterion, with a score of 0 representing no foreign body sensation and a score of 10 representing strong foreign body sensation. A total of 27 patients with a self-scoring of foreign body sensation higher than 6 points after surgery for eye diseases such as cataract or glaucoma were selected.
[0171] Test group: 14 subjects, 8 males and 6 females, aged 63-72 years. The 0.05% ophthalmic solution prepared in Example 1 was instilled into the eyes at 1 drop / eye / time, 3 times / day, with 4-hour intervals between each administration, for 7 consecutive days.
[0172] Control group: 13 cases, 6 males and 7 females, aged 63-73 years. Sodium hyaluronate eye drops were administered at 1 drop / eye / time, 3 times / day, 4 hours apart for 7 consecutive days.
[0173] The self-rating of foreign body sensation in the two groups of patients was observed after administration.
[0174] Results: The results of comparing the patients' foreign body sensation after drug administration between the two groups are shown in Table 18. Statistics were performed using the independent sample T-test for two groups. Compared with the control group, i.e., comparing between groups, the foreign body sensation scores of the patients in the test group were significantly reduced at 1 hour, 3 days, and 7 days after administration (P<0.05 or P<0.01); compared with the foreign body sensation scores before administration, i.e., comparing within groups, the foreign body sensation scores of the patients in the test group were significantly reduced at 1 hour, 3 days, and 7 days after administration (P<0.05 or P<0.01), and the foreign body sensation of the patients in the test group was more obviously reduced with the increase in the number of administrations. The results showed that the ophthalmic solution of the present disclosure can reduce postoperative eye discomfort, mainly manifested as foreign body sensation, and promote postoperative wound healing.
[0175] [Table 19]
[0176] Example 8 Studies to treat, mitigate, or alleviate ocular surface disease caused by meibomian gland dysfunction (MGD) Ninety patients who were diagnosed with moderate or severe MGD by an ophthalmologist were selected (if the patient had moderate or severe MGD in both eyes, the right eye of each patient was selected as the observation eye). All patients were randomly divided into a control group and a study group, with 45 cases in each group.
[0177] All patients were given basic treatment, and the specific operation methods were: (1) Cleaning the eyelid margin: Soak a medical cotton swab in 0.9% sodium chloride injection, and use this cotton swab to clean the eyelid margin once a day; (2) Hot compress: Put on the eye pad of Greenhouse Mirror, adjust the rubber band for comfort, turn on the power, and select mode 2 (negative pressure massage +40℃ circular hot compress), 15 minutes / time, 1 time / day.
[0178] Test group: 23 men and 22 women, average age (37.6±7.1) years. The 0.05% ophthalmic solution prepared in Example 1 was instilled into the eyes at 1 drop / eye / time, 3 times / day with 4-hour intervals for 7 consecutive days.
[0179] Control group: 24 men and 21 women, mean age (36.9 ± 7.0) years, received polyvinyl alcohol eye drops, 1 drop / eye / time, 3 doses / day for 7 consecutive days, with an interval of 4 hours between each dose.
[0180] Degree of congestion of the palpebral conjunctiva: Observed under a slit lamp microscope using diffuse illumination. 0 points: no congestion or slight congestion of the conjunctiva at the lid margin, no telangiectasia at the orifices of the meibomian glands; 1 point: congestion of the conjunctiva at the lid margin, but the congestion is limited to the fornix, the blood vessels are bright red, and there are no telangiectasias at the orifices of the meibomian glands; 2 points: congestion of the conjunctiva at the lid margin, the blood vessels are dark red, have an unclear course, and there are telangiectasias at the orifices of the meibomian glands, the extent of which is less than 1 / 2 of the lid margin; 3 points: diffuse congestion of the conjunctiva at the lid margin, the blood vessels are reddish purple, the texture of the tarsal plate is unclear, and there are telangiectasias at the orifices of the meibomian glands, the extent of which is more than 1 / 2 of the lid margin.
[0181] The results of the conjunctival congestion of patients in two groups are shown in Table 19. After 7 days of administration for treatment, the conjunctival congestion score of patients in the test group was significantly reduced compared with that before treatment (P<0.05), while the difference in the conjunctival congestion score of the control group was small (P>0.05); after treatment, the conjunctival congestion score of patients in the test group was significantly reduced compared with that of the control group (P<0.05). The above results suggested that the ophthalmic solution of Example 1 can significantly relieve eyelid conjunctival congestion in patients with MGD.
[0182] [Table 20]
[0183] Although certain embodiments have been described, it is understood that replacements, modifications, variations, improvements, and substantial equivalents of the above embodiments may exist or are not currently foreseeable to the applicant or those skilled in the art, and therefore the appended claims as filed and as they may be amended are intended to cover all such replacements, modifications, variations, improvements, and substantial equivalents.
Claims
1. Use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating non-dry eye ocular surface diseases and / or conditions.
2. Use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with corneal epithelial injury.
3. Use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions caused by diabetes.
4. Use of alanyl-glutamine in the manufacture of a medicament for treating, reducing or alleviating ocular surface diseases and / or conditions associated with diabetes-induced keratopathy.
5. Use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with recurrent corneal epithelial erosion.
6. Use of alanyl-glutamine in the manufacture of a medicament for treating, reducing or alleviating ocular surface diseases and / or conditions associated with surgery-related recurrent corneal epithelial erosion.
7. Use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with tissue repair and healing following ocular trauma and / or surgery.
8. Use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with conjunctivitis.
9. Use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with ocular congestion.
10. Use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with meibomian gland dysfunction.
11. Use of alanyl-glutamine in the manufacture of a medicament for treating, alleviating or ameliorating ocular surface diseases and / or conditions associated with eye strain.
12. Use of alanyl-glutamine in the manufacture of a medicament for preventing myopia.
13. Use of alanyl-glutamine in the manufacture of beauty and health care products for reducing or alleviating eye strain.
14. Use of alanyl-glutamine in the manufacture of beauty and health care products for preventing myopia.
15. Use of alanyl-glutamine in the manufacture of beauty and health care products for the eyes.
16. 1. An ophthalmic composition comprising alanyl-glutamine and an ophthalmically acceptable excipient, the ophthalmic composition being in the form of an eye drop, suspension, gel, eye ointment, emulsion, eye pad, eye patch, eye mask, eye cream, spray, injectable or indwelling solution.
17. 17. The ophthalmic composition of claim 16, in isotonic or hypotonic form.
18. The ophthalmic composition according to claim 16 or 17, wherein the concentration of alanyl-glutamine in the ophthalmic composition is from 0.05% w / w to 10% w / w.
19. 19. The ophthalmic composition of any one of claims 16 to 18, wherein the ophthalmically acceptable excipient comprises one or more of an osmolality adjusting agent, a bacteriostat, a viscosity increasing agent, a pH adjusting agent, a stabilizer, a surfactant, a humectant, and the like.
20. 1. A method of treating, alleviating or ameliorating non-dry eye ocular surface diseases and / or conditions, ocular surface diseases and / or conditions associated with corneal epithelial injury, ocular surface diseases and / or conditions caused by diabetes, ocular surface diseases and / or conditions associated with diabetic keratopathy, ocular surface diseases and / or conditions associated with recurrent corneal epithelial erosion, ocular surface diseases and / or conditions associated with surgery-related recurrent corneal epithelial erosion, ocular surface diseases and / or conditions associated with tissue repair and healing following ocular trauma and / or surgery, ocular surface diseases and / or conditions associated with conjunctivitis, ocular surface diseases and / or conditions associated with ocular congestion, ocular surface diseases and / or conditions associated with meibomian gland dysfunction, eye strain, ocular surface diseases and / or conditions associated with myopia, comprising administering to a subject a therapeutically effective amount of alanyl-glutamine.
21. 20. A method of treating, alleviating or alleviating non-dry eye ocular surface diseases and / or conditions, ocular surface diseases and / or conditions associated with corneal epithelial injury, ocular surface diseases and / or conditions caused by diabetes, ocular surface diseases and / or conditions associated with diabetic keratopathy, ocular surface diseases and / or conditions associated with recurrent corneal epithelial erosion, ocular surface diseases and / or conditions associated with surgery-related recurrent corneal epithelial erosion, ocular surface diseases and / or conditions associated with tissue repair and healing after ocular trauma and / or surgery, ocular surface diseases and / or conditions associated with conjunctivitis, ocular surface diseases and / or conditions associated with ocular congestion, ocular surface diseases and / or conditions associated with meibomian gland dysfunction, eye strain, ocular surface diseases and / or conditions associated with myopia, comprising administering to a subject a therapeutically effective amount of an ophthalmic composition according to any one of claims 16 to 19.
Citation Information
Patent Citations
Ophthalmic pharmaceutical composition, its preparation method, and its application
JP2021512172A
